In this webinar, Dr. Marlise Luskin from Dana Farber Cancer Institute will define high-risk MDS versus low-risk MDS, impact for patients and what treatment options are available.
This webinar is brought to you by the generous support of Celgene, Takeda and Jazz Pharmaceuticals.
4 окт 2024